Anti-obesity Drugs Market Size, Share, Growth, Analysis, 2034

GLP-1 Receptor Agonists
Dual GIP/GLP-1 Agonists
Triple or Multi-Receptor Agonists
Centrally Acting Sympathomimetics
Peripherally Acting Lipase Inhibitors

Prescription Drugs
OTC Drugs

Hospital Pharmacies
Drug Stores & Retail Pharmacies
E-commerce

North America
1. North America Anti-obesity Drugs Market By Drug Class 2022-2034 (USD MILLION/ Units)
  1. GLP-1 Receptor Agonists
  2. Dual GIP/GLP-1 Agonists
  3. Triple or Multi-Receptor Agonists
  4. Centrally Acting Sympathomimetics
  5. Peripherally Acting Lipase Inhibitors
2. North America Anti-obesity Drugs Market By Type 2022-2034 (USD MILLION/ Units)
  1. Prescription Drugs
  2. OTC Drugs
3. North America Anti-obesity Drugs Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
  1. Hospital Pharmacies
  2. Drug Stores & Retail Pharmacies
  3. E-commerce
4. U.S. Anti-obesity Drugs Market
  1. U.S. Anti-obesity Drugs Market By Drug Class 2022-2034 (USD MILLION/ Units)
    1. GLP-1 Receptor Agonists
    2. Dual GIP/GLP-1 Agonists
    3. Triple or Multi-Receptor Agonists
    4. Centrally Acting Sympathomimetics
    5. Peripherally Acting Lipase Inhibitors
  2. U.S. Anti-obesity Drugs Market By Type 2022-2034 (USD MILLION/ Units)
    1. Prescription Drugs
    2. OTC Drugs
  3. U.S. Anti-obesity Drugs Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
    1. Hospital Pharmacies
    2. Drug Stores & Retail Pharmacies
    3. E-commerce
5. Canada Anti-obesity Drugs Market
  1. Canada Anti-obesity Drugs Market By Drug Class 2022-2034 (USD MILLION/ Units)
    1. GLP-1 Receptor Agonists
    2. Dual GIP/GLP-1 Agonists
    3. Triple or Multi-Receptor Agonists
    4. Centrally Acting Sympathomimetics
    5. Peripherally Acting Lipase Inhibitors
  2. Canada Anti-obesity Drugs Market By Type 2022-2034 (USD MILLION/ Units)
    1. Prescription Drugs
    2. OTC Drugs
  3. Canada Anti-obesity Drugs Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
    1. Hospital Pharmacies
    2. Drug Stores & Retail Pharmacies
    3. E-commerce
Europe
1. Europe Anti-obesity Drugs Market By Drug Class 2022-2034 (USD MILLION/ Units)
  1. GLP-1 Receptor Agonists
  2. Dual GIP/GLP-1 Agonists
  3. Triple or Multi-Receptor Agonists
  4. Centrally Acting Sympathomimetics
  5. Peripherally Acting Lipase Inhibitors
2. Europe Anti-obesity Drugs Market By Type 2022-2034 (USD MILLION/ Units)
  1. Prescription Drugs
  2. OTC Drugs
3. Europe Anti-obesity Drugs Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
  1. Hospital Pharmacies
  2. Drug Stores & Retail Pharmacies
  3. E-commerce
4. U.K. Anti-obesity Drugs Market
  1. U.K. Anti-obesity Drugs Market By Drug Class 2022-2034 (USD MILLION/ Units)
    1. GLP-1 Receptor Agonists
    2. Dual GIP/GLP-1 Agonists
    3. Triple or Multi-Receptor Agonists
    4. Centrally Acting Sympathomimetics
    5. Peripherally Acting Lipase Inhibitors
  2. U.K. Anti-obesity Drugs Market By Type 2022-2034 (USD MILLION/ Units)
    1. Prescription Drugs
    2. OTC Drugs
  3. U.K. Anti-obesity Drugs Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
    1. Hospital Pharmacies
    2. Drug Stores & Retail Pharmacies
    3. E-commerce
5. Germany Anti-obesity Drugs Market
  1. Germany Anti-obesity Drugs Market By Drug Class 2022-2034 (USD MILLION/ Units)
    1. GLP-1 Receptor Agonists
    2. Dual GIP/GLP-1 Agonists
    3. Triple or Multi-Receptor Agonists
    4. Centrally Acting Sympathomimetics
    5. Peripherally Acting Lipase Inhibitors
  2. Germany Anti-obesity Drugs Market By Type 2022-2034 (USD MILLION/ Units)
    1. Prescription Drugs
    2. OTC Drugs
  3. Germany Anti-obesity Drugs Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
    1. Hospital Pharmacies
    2. Drug Stores & Retail Pharmacies
    3. E-commerce
6. France Anti-obesity Drugs Market
  1. France Anti-obesity Drugs Market By Drug Class 2022-2034 (USD MILLION/ Units)
    1. GLP-1 Receptor Agonists
    2. Dual GIP/GLP-1 Agonists
    3. Triple or Multi-Receptor Agonists
    4. Centrally Acting Sympathomimetics
    5. Peripherally Acting Lipase Inhibitors
  2. France Anti-obesity Drugs Market By Type 2022-2034 (USD MILLION/ Units)
    1. Prescription Drugs
    2. OTC Drugs
  3. France Anti-obesity Drugs Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
    1. Hospital Pharmacies
    2. Drug Stores & Retail Pharmacies
    3. E-commerce
7. Spain Anti-obesity Drugs Market
  1. Spain Anti-obesity Drugs Market By Drug Class 2022-2034 (USD MILLION/ Units)
    1. GLP-1 Receptor Agonists
    2. Dual GIP/GLP-1 Agonists
    3. Triple or Multi-Receptor Agonists
    4. Centrally Acting Sympathomimetics
    5. Peripherally Acting Lipase Inhibitors
  2. Spain Anti-obesity Drugs Market By Type 2022-2034 (USD MILLION/ Units)
    1. Prescription Drugs
    2. OTC Drugs
  3. Spain Anti-obesity Drugs Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
    1. Hospital Pharmacies
    2. Drug Stores & Retail Pharmacies
    3. E-commerce
8. Italy Anti-obesity Drugs Market
  1. Italy Anti-obesity Drugs Market By Drug Class 2022-2034 (USD MILLION/ Units)
    1. GLP-1 Receptor Agonists
    2. Dual GIP/GLP-1 Agonists
    3. Triple or Multi-Receptor Agonists
    4. Centrally Acting Sympathomimetics
    5. Peripherally Acting Lipase Inhibitors
  2. Italy Anti-obesity Drugs Market By Type 2022-2034 (USD MILLION/ Units)
    1. Prescription Drugs
    2. OTC Drugs
  3. Italy Anti-obesity Drugs Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
    1. Hospital Pharmacies
    2. Drug Stores & Retail Pharmacies
    3. E-commerce
9. Russia Anti-obesity Drugs Market
  1. Russia Anti-obesity Drugs Market By Drug Class 2022-2034 (USD MILLION/ Units)
    1. GLP-1 Receptor Agonists
    2. Dual GIP/GLP-1 Agonists
    3. Triple or Multi-Receptor Agonists
    4. Centrally Acting Sympathomimetics
    5. Peripherally Acting Lipase Inhibitors
  2. Russia Anti-obesity Drugs Market By Type 2022-2034 (USD MILLION/ Units)
    1. Prescription Drugs
    2. OTC Drugs
  3. Russia Anti-obesity Drugs Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
    1. Hospital Pharmacies
    2. Drug Stores & Retail Pharmacies
    3. E-commerce
10. Nordic Anti-obesity Drugs Market
  1. Nordic Anti-obesity Drugs Market By Drug Class 2022-2034 (USD MILLION/ Units)
    1. GLP-1 Receptor Agonists
    2. Dual GIP/GLP-1 Agonists
    3. Triple or Multi-Receptor Agonists
    4. Centrally Acting Sympathomimetics
    5. Peripherally Acting Lipase Inhibitors
  2. Nordic Anti-obesity Drugs Market By Type 2022-2034 (USD MILLION/ Units)
    1. Prescription Drugs
    2. OTC Drugs
  3. Nordic Anti-obesity Drugs Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
    1. Hospital Pharmacies
    2. Drug Stores & Retail Pharmacies
    3. E-commerce
11. Benelux Anti-obesity Drugs Market
  1. Benelux Anti-obesity Drugs Market By Drug Class 2022-2034 (USD MILLION/ Units)
    1. GLP-1 Receptor Agonists
    2. Dual GIP/GLP-1 Agonists
    3. Triple or Multi-Receptor Agonists
    4. Centrally Acting Sympathomimetics
    5. Peripherally Acting Lipase Inhibitors
  2. Benelux Anti-obesity Drugs Market By Type 2022-2034 (USD MILLION/ Units)
    1. Prescription Drugs
    2. OTC Drugs
  3. Benelux Anti-obesity Drugs Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
    1. Hospital Pharmacies
    2. Drug Stores & Retail Pharmacies
    3. E-commerce
12. Rest of Europe Anti-obesity Drugs Market
  1. Rest of Europe Anti-obesity Drugs Market By Drug Class 2022-2034 (USD MILLION/ Units)
    1. GLP-1 Receptor Agonists
    2. Dual GIP/GLP-1 Agonists
    3. Triple or Multi-Receptor Agonists
    4. Centrally Acting Sympathomimetics
    5. Peripherally Acting Lipase Inhibitors
  2. Rest of Europe Anti-obesity Drugs Market By Type 2022-2034 (USD MILLION/ Units)
    1. Prescription Drugs
    2. OTC Drugs
  3. Rest of Europe Anti-obesity Drugs Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
    1. Hospital Pharmacies
    2. Drug Stores & Retail Pharmacies
    3. E-commerce
APAC
1. APAC Anti-obesity Drugs Market By Drug Class 2022-2034 (USD MILLION/ Units)
  1. GLP-1 Receptor Agonists
  2. Dual GIP/GLP-1 Agonists
  3. Triple or Multi-Receptor Agonists
  4. Centrally Acting Sympathomimetics
  5. Peripherally Acting Lipase Inhibitors
2. APAC Anti-obesity Drugs Market By Type 2022-2034 (USD MILLION/ Units)
  1. Prescription Drugs
  2. OTC Drugs
3. APAC Anti-obesity Drugs Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
  1. Hospital Pharmacies
  2. Drug Stores & Retail Pharmacies
  3. E-commerce
4. China Anti-obesity Drugs Market
  1. China Anti-obesity Drugs Market By Drug Class 2022-2034 (USD MILLION/ Units)
    1. GLP-1 Receptor Agonists
    2. Dual GIP/GLP-1 Agonists
    3. Triple or Multi-Receptor Agonists
    4. Centrally Acting Sympathomimetics
    5. Peripherally Acting Lipase Inhibitors
  2. China Anti-obesity Drugs Market By Type 2022-2034 (USD MILLION/ Units)
    1. Prescription Drugs
    2. OTC Drugs
  3. China Anti-obesity Drugs Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
    1. Hospital Pharmacies
    2. Drug Stores & Retail Pharmacies
    3. E-commerce
5. Korea Anti-obesity Drugs Market
  1. Korea Anti-obesity Drugs Market By Drug Class 2022-2034 (USD MILLION/ Units)
    1. GLP-1 Receptor Agonists
    2. Dual GIP/GLP-1 Agonists
    3. Triple or Multi-Receptor Agonists
    4. Centrally Acting Sympathomimetics
    5. Peripherally Acting Lipase Inhibitors
  2. Korea Anti-obesity Drugs Market By Type 2022-2034 (USD MILLION/ Units)
    1. Prescription Drugs
    2. OTC Drugs
  3. Korea Anti-obesity Drugs Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
    1. Hospital Pharmacies
    2. Drug Stores & Retail Pharmacies
    3. E-commerce
6. Japan Anti-obesity Drugs Market
  1. Japan Anti-obesity Drugs Market By Drug Class 2022-2034 (USD MILLION/ Units)
    1. GLP-1 Receptor Agonists
    2. Dual GIP/GLP-1 Agonists
    3. Triple or Multi-Receptor Agonists
    4. Centrally Acting Sympathomimetics
    5. Peripherally Acting Lipase Inhibitors
  2. Japan Anti-obesity Drugs Market By Type 2022-2034 (USD MILLION/ Units)
    1. Prescription Drugs
    2. OTC Drugs
  3. Japan Anti-obesity Drugs Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
    1. Hospital Pharmacies
    2. Drug Stores & Retail Pharmacies
    3. E-commerce
7. India Anti-obesity Drugs Market
  1. India Anti-obesity Drugs Market By Drug Class 2022-2034 (USD MILLION/ Units)
    1. GLP-1 Receptor Agonists
    2. Dual GIP/GLP-1 Agonists
    3. Triple or Multi-Receptor Agonists
    4. Centrally Acting Sympathomimetics
    5. Peripherally Acting Lipase Inhibitors
  2. India Anti-obesity Drugs Market By Type 2022-2034 (USD MILLION/ Units)
    1. Prescription Drugs
    2. OTC Drugs
  3. India Anti-obesity Drugs Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
    1. Hospital Pharmacies
    2. Drug Stores & Retail Pharmacies
    3. E-commerce
8. Australia Anti-obesity Drugs Market
  1. Australia Anti-obesity Drugs Market By Drug Class 2022-2034 (USD MILLION/ Units)
    1. GLP-1 Receptor Agonists
    2. Dual GIP/GLP-1 Agonists
    3. Triple or Multi-Receptor Agonists
    4. Centrally Acting Sympathomimetics
    5. Peripherally Acting Lipase Inhibitors
  2. Australia Anti-obesity Drugs Market By Type 2022-2034 (USD MILLION/ Units)
    1. Prescription Drugs
    2. OTC Drugs
  3. Australia Anti-obesity Drugs Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
    1. Hospital Pharmacies
    2. Drug Stores & Retail Pharmacies
    3. E-commerce
9. Taiwan Anti-obesity Drugs Market
  1. Taiwan Anti-obesity Drugs Market By Drug Class 2022-2034 (USD MILLION/ Units)
    1. GLP-1 Receptor Agonists
    2. Dual GIP/GLP-1 Agonists
    3. Triple or Multi-Receptor Agonists
    4. Centrally Acting Sympathomimetics
    5. Peripherally Acting Lipase Inhibitors
  2. Taiwan Anti-obesity Drugs Market By Type 2022-2034 (USD MILLION/ Units)
    1. Prescription Drugs
    2. OTC Drugs
  3. Taiwan Anti-obesity Drugs Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
    1. Hospital Pharmacies
    2. Drug Stores & Retail Pharmacies
    3. E-commerce
10. South East Asia Anti-obesity Drugs Market
  1. South East Asia Anti-obesity Drugs Market By Drug Class 2022-2034 (USD MILLION/ Units)
    1. GLP-1 Receptor Agonists
    2. Dual GIP/GLP-1 Agonists
    3. Triple or Multi-Receptor Agonists
    4. Centrally Acting Sympathomimetics
    5. Peripherally Acting Lipase Inhibitors
  2. South East Asia Anti-obesity Drugs Market By Type 2022-2034 (USD MILLION/ Units)
    1. Prescription Drugs
    2. OTC Drugs
  3. South East Asia Anti-obesity Drugs Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
    1. Hospital Pharmacies
    2. Drug Stores & Retail Pharmacies
    3. E-commerce
11. Rest of Asia-Pacific Anti-obesity Drugs Market
  1. Rest of Asia-Pacific Anti-obesity Drugs Market By Drug Class 2022-2034 (USD MILLION/ Units)
    1. GLP-1 Receptor Agonists
    2. Dual GIP/GLP-1 Agonists
    3. Triple or Multi-Receptor Agonists
    4. Centrally Acting Sympathomimetics
    5. Peripherally Acting Lipase Inhibitors
  2. Rest of Asia-Pacific Anti-obesity Drugs Market By Type 2022-2034 (USD MILLION/ Units)
    1. Prescription Drugs
    2. OTC Drugs
  3. Rest of Asia-Pacific Anti-obesity Drugs Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
    1. Hospital Pharmacies
    2. Drug Stores & Retail Pharmacies
    3. E-commerce
Middle East and Africa
1. Middle East and Africa Anti-obesity Drugs Market By Drug Class 2022-2034 (USD MILLION/ Units)
  1. GLP-1 Receptor Agonists
  2. Dual GIP/GLP-1 Agonists
  3. Triple or Multi-Receptor Agonists
  4. Centrally Acting Sympathomimetics
  5. Peripherally Acting Lipase Inhibitors
2. Middle East and Africa Anti-obesity Drugs Market By Type 2022-2034 (USD MILLION/ Units)
  1. Prescription Drugs
  2. OTC Drugs
3. Middle East and Africa Anti-obesity Drugs Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
  1. Hospital Pharmacies
  2. Drug Stores & Retail Pharmacies
  3. E-commerce
4. UAE Anti-obesity Drugs Market
  1. UAE Anti-obesity Drugs Market By Drug Class 2022-2034 (USD MILLION/ Units)
    1. GLP-1 Receptor Agonists
    2. Dual GIP/GLP-1 Agonists
    3. Triple or Multi-Receptor Agonists
    4. Centrally Acting Sympathomimetics
    5. Peripherally Acting Lipase Inhibitors
  2. UAE Anti-obesity Drugs Market By Type 2022-2034 (USD MILLION/ Units)
    1. Prescription Drugs
    2. OTC Drugs
  3. UAE Anti-obesity Drugs Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
    1. Hospital Pharmacies
    2. Drug Stores & Retail Pharmacies
    3. E-commerce
5. Turkey Anti-obesity Drugs Market
  1. Turkey Anti-obesity Drugs Market By Drug Class 2022-2034 (USD MILLION/ Units)
    1. GLP-1 Receptor Agonists
    2. Dual GIP/GLP-1 Agonists
    3. Triple or Multi-Receptor Agonists
    4. Centrally Acting Sympathomimetics
    5. Peripherally Acting Lipase Inhibitors
  2. Turkey Anti-obesity Drugs Market By Type 2022-2034 (USD MILLION/ Units)
    1. Prescription Drugs
    2. OTC Drugs
  3. Turkey Anti-obesity Drugs Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
    1. Hospital Pharmacies
    2. Drug Stores & Retail Pharmacies
    3. E-commerce
6. Saudi Arabia Anti-obesity Drugs Market
  1. Saudi Arabia Anti-obesity Drugs Market By Drug Class 2022-2034 (USD MILLION/ Units)
    1. GLP-1 Receptor Agonists
    2. Dual GIP/GLP-1 Agonists
    3. Triple or Multi-Receptor Agonists
    4. Centrally Acting Sympathomimetics
    5. Peripherally Acting Lipase Inhibitors
  2. Saudi Arabia Anti-obesity Drugs Market By Type 2022-2034 (USD MILLION/ Units)
    1. Prescription Drugs
    2. OTC Drugs
  3. Saudi Arabia Anti-obesity Drugs Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
    1. Hospital Pharmacies
    2. Drug Stores & Retail Pharmacies
    3. E-commerce
7. South Africa Anti-obesity Drugs Market
  1. South Africa Anti-obesity Drugs Market By Drug Class 2022-2034 (USD MILLION/ Units)
    1. GLP-1 Receptor Agonists
    2. Dual GIP/GLP-1 Agonists
    3. Triple or Multi-Receptor Agonists
    4. Centrally Acting Sympathomimetics
    5. Peripherally Acting Lipase Inhibitors
  2. South Africa Anti-obesity Drugs Market By Type 2022-2034 (USD MILLION/ Units)
    1. Prescription Drugs
    2. OTC Drugs
  3. South Africa Anti-obesity Drugs Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
    1. Hospital Pharmacies
    2. Drug Stores & Retail Pharmacies
    3. E-commerce
8. Egypt Anti-obesity Drugs Market
  1. Egypt Anti-obesity Drugs Market By Drug Class 2022-2034 (USD MILLION/ Units)
    1. GLP-1 Receptor Agonists
    2. Dual GIP/GLP-1 Agonists
    3. Triple or Multi-Receptor Agonists
    4. Centrally Acting Sympathomimetics
    5. Peripherally Acting Lipase Inhibitors
  2. Egypt Anti-obesity Drugs Market By Type 2022-2034 (USD MILLION/ Units)
    1. Prescription Drugs
    2. OTC Drugs
  3. Egypt Anti-obesity Drugs Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
    1. Hospital Pharmacies
    2. Drug Stores & Retail Pharmacies
    3. E-commerce
9. Nigeria Anti-obesity Drugs Market
  1. Nigeria Anti-obesity Drugs Market By Drug Class 2022-2034 (USD MILLION/ Units)
    1. GLP-1 Receptor Agonists
    2. Dual GIP/GLP-1 Agonists
    3. Triple or Multi-Receptor Agonists
    4. Centrally Acting Sympathomimetics
    5. Peripherally Acting Lipase Inhibitors
  2. Nigeria Anti-obesity Drugs Market By Type 2022-2034 (USD MILLION/ Units)
    1. Prescription Drugs
    2. OTC Drugs
  3. Nigeria Anti-obesity Drugs Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
    1. Hospital Pharmacies
    2. Drug Stores & Retail Pharmacies
    3. E-commerce
10. Rest of MEA Anti-obesity Drugs Market
  1. Rest of MEA Anti-obesity Drugs Market By Drug Class 2022-2034 (USD MILLION/ Units)
    1. GLP-1 Receptor Agonists
    2. Dual GIP/GLP-1 Agonists
    3. Triple or Multi-Receptor Agonists
    4. Centrally Acting Sympathomimetics
    5. Peripherally Acting Lipase Inhibitors
  2. Rest of MEA Anti-obesity Drugs Market By Type 2022-2034 (USD MILLION/ Units)
    1. Prescription Drugs
    2. OTC Drugs
  3. Rest of MEA Anti-obesity Drugs Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
    1. Hospital Pharmacies
    2. Drug Stores & Retail Pharmacies
    3. E-commerce
LATAM
1. LATAM Anti-obesity Drugs Market By Drug Class 2022-2034 (USD MILLION/ Units)
  1. GLP-1 Receptor Agonists
  2. Dual GIP/GLP-1 Agonists
  3. Triple or Multi-Receptor Agonists
  4. Centrally Acting Sympathomimetics
  5. Peripherally Acting Lipase Inhibitors
2. LATAM Anti-obesity Drugs Market By Type 2022-2034 (USD MILLION/ Units)
  1. Prescription Drugs
  2. OTC Drugs
3. LATAM Anti-obesity Drugs Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
  1. Hospital Pharmacies
  2. Drug Stores & Retail Pharmacies
  3. E-commerce
4. Brazil Anti-obesity Drugs Market
  1. Brazil Anti-obesity Drugs Market By Drug Class 2022-2034 (USD MILLION/ Units)
    1. GLP-1 Receptor Agonists
    2. Dual GIP/GLP-1 Agonists
    3. Triple or Multi-Receptor Agonists
    4. Centrally Acting Sympathomimetics
    5. Peripherally Acting Lipase Inhibitors
  2. Brazil Anti-obesity Drugs Market By Type 2022-2034 (USD MILLION/ Units)
    1. Prescription Drugs
    2. OTC Drugs
  3. Brazil Anti-obesity Drugs Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
    1. Hospital Pharmacies
    2. Drug Stores & Retail Pharmacies
    3. E-commerce
5. Mexico Anti-obesity Drugs Market
  1. Mexico Anti-obesity Drugs Market By Drug Class 2022-2034 (USD MILLION/ Units)
    1. GLP-1 Receptor Agonists
    2. Dual GIP/GLP-1 Agonists
    3. Triple or Multi-Receptor Agonists
    4. Centrally Acting Sympathomimetics
    5. Peripherally Acting Lipase Inhibitors
  2. Mexico Anti-obesity Drugs Market By Type 2022-2034 (USD MILLION/ Units)
    1. Prescription Drugs
    2. OTC Drugs
  3. Mexico Anti-obesity Drugs Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
    1. Hospital Pharmacies
    2. Drug Stores & Retail Pharmacies
    3. E-commerce
6. Argentina Anti-obesity Drugs Market
  1. Argentina Anti-obesity Drugs Market By Drug Class 2022-2034 (USD MILLION/ Units)
    1. GLP-1 Receptor Agonists
    2. Dual GIP/GLP-1 Agonists
    3. Triple or Multi-Receptor Agonists
    4. Centrally Acting Sympathomimetics
    5. Peripherally Acting Lipase Inhibitors
  2. Argentina Anti-obesity Drugs Market By Type 2022-2034 (USD MILLION/ Units)
    1. Prescription Drugs
    2. OTC Drugs
  3. Argentina Anti-obesity Drugs Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
    1. Hospital Pharmacies
    2. Drug Stores & Retail Pharmacies
    3. E-commerce
7. Chile Anti-obesity Drugs Market
  1. Chile Anti-obesity Drugs Market By Drug Class 2022-2034 (USD MILLION/ Units)
    1. GLP-1 Receptor Agonists
    2. Dual GIP/GLP-1 Agonists
    3. Triple or Multi-Receptor Agonists
    4. Centrally Acting Sympathomimetics
    5. Peripherally Acting Lipase Inhibitors
  2. Chile Anti-obesity Drugs Market By Type 2022-2034 (USD MILLION/ Units)
    1. Prescription Drugs
    2. OTC Drugs
  3. Chile Anti-obesity Drugs Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
    1. Hospital Pharmacies
    2. Drug Stores & Retail Pharmacies
    3. E-commerce
8. Colombia Anti-obesity Drugs Market
  1. Colombia Anti-obesity Drugs Market By Drug Class 2022-2034 (USD MILLION/ Units)
    1. GLP-1 Receptor Agonists
    2. Dual GIP/GLP-1 Agonists
    3. Triple or Multi-Receptor Agonists
    4. Centrally Acting Sympathomimetics
    5. Peripherally Acting Lipase Inhibitors
  2. Colombia Anti-obesity Drugs Market By Type 2022-2034 (USD MILLION/ Units)
    1. Prescription Drugs
    2. OTC Drugs
  3. Colombia Anti-obesity Drugs Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
    1. Hospital Pharmacies
    2. Drug Stores & Retail Pharmacies
    3. E-commerce
9. Rest of LATAM Anti-obesity Drugs Market
  1. Rest of LATAM Anti-obesity Drugs Market By Drug Class 2022-2034 (USD MILLION/ Units)
    1. GLP-1 Receptor Agonists
    2. Dual GIP/GLP-1 Agonists
    3. Triple or Multi-Receptor Agonists
    4. Centrally Acting Sympathomimetics
    5. Peripherally Acting Lipase Inhibitors
  2. Rest of LATAM Anti-obesity Drugs Market By Type 2022-2034 (USD MILLION/ Units)
    1. Prescription Drugs
    2. OTC Drugs
  3. Rest of LATAM Anti-obesity Drugs Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
    1. Hospital Pharmacies
    2. Drug Stores & Retail Pharmacies
    3. E-commerce

Market Segmentation